Joint Mexican position document on the treatment of atrial fibrillation
Abstract Atrial fibrillation (AF) is a frequent arrhythmia; its prevalence is near 2% in the general population; in Mexico, more than one-half million people are affected. AF needs to be considered as a public health problem. Because AF is an independent risk factor associated with mortality, due to embolic events, heart failure, or sudden death; early diagnosis is of utmost importance. In unstable patients with a recent onset of AF, electrical cardioversion should be practiced. In stable patients, once thromboembolic measures have been taken, it is necessary to assess whether it is reasonable to administer an antiarrhythmic drug to restore sinus rhythm or performed electrical cardioversion. For recidivating cases of paroxysmal and persistent presentation, the most effective strategy is performed pulmonary vein isolation with either radiofrequency or cryoballoon energy. Permanent AF is that in which recovery of sinus rhythm is not possible, the distinguishing feature of this phase is the uncontrollable variability of the ventricular frequency and could be treated pharmacologically with atrioventricular (AV) nodal blockers or with a VVIR pacemaker plus AV nodal ablation. The presence of AF has long been associated with the development of cerebral and systemic (pulmonary, limb, coronary, renal, and visceral) embolism. The prevention of embolisms in valvular AF should perform with Vitamin K antagonists (VKA). For patients with AF not associated with mitral stenosis or a mechanical valve prosthesis, a choice can be made between anticoagulant drugs, VKA, or direct oral anticoagulants. Antiplatelet agents have the weakest effect in preventing embolism.
Main Authors: | , , , , , , |
---|---|
Format: | Digital revista |
Language: | English |
Published: |
Instituto Nacional de Cardiología Ignacio Chávez
2020
|
Online Access: | http://www.scielo.org.mx/scielo.php?script=sci_arttext&pid=S1405-99402020000100069 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
id |
oai:scielo:S1405-99402020000100069 |
---|---|
record_format |
ojs |
spelling |
oai:scielo:S1405-994020200001000692020-10-21Joint Mexican position document on the treatment of atrial fibrillationRodríguez-Diez,GerardoMárquez,Manlio F.Iturralde-Torres,PedroMolina-Fernández de L.,Luis G.Pozas-Garza,GerardoCordero-Cabra,AlejandroRojel-Martínez,Ulises Atrial fibrillation Drug treatment Tromboprofilaxis Cryoballoon ablation Radiofrequency ablation Abstract Atrial fibrillation (AF) is a frequent arrhythmia; its prevalence is near 2% in the general population; in Mexico, more than one-half million people are affected. AF needs to be considered as a public health problem. Because AF is an independent risk factor associated with mortality, due to embolic events, heart failure, or sudden death; early diagnosis is of utmost importance. In unstable patients with a recent onset of AF, electrical cardioversion should be practiced. In stable patients, once thromboembolic measures have been taken, it is necessary to assess whether it is reasonable to administer an antiarrhythmic drug to restore sinus rhythm or performed electrical cardioversion. For recidivating cases of paroxysmal and persistent presentation, the most effective strategy is performed pulmonary vein isolation with either radiofrequency or cryoballoon energy. Permanent AF is that in which recovery of sinus rhythm is not possible, the distinguishing feature of this phase is the uncontrollable variability of the ventricular frequency and could be treated pharmacologically with atrioventricular (AV) nodal blockers or with a VVIR pacemaker plus AV nodal ablation. The presence of AF has long been associated with the development of cerebral and systemic (pulmonary, limb, coronary, renal, and visceral) embolism. The prevention of embolisms in valvular AF should perform with Vitamin K antagonists (VKA). For patients with AF not associated with mitral stenosis or a mechanical valve prosthesis, a choice can be made between anticoagulant drugs, VKA, or direct oral anticoagulants. Antiplatelet agents have the weakest effect in preventing embolism.info:eu-repo/semantics/openAccessInstituto Nacional de Cardiología Ignacio ChávezArchivos de cardiología de México v.90 n.1 20202020-03-01info:eu-repo/semantics/articletext/htmlhttp://www.scielo.org.mx/scielo.php?script=sci_arttext&pid=S1405-99402020000100069en10.24875/acme.m20000096 |
institution |
SCIELO |
collection |
OJS |
country |
México |
countrycode |
MX |
component |
Revista |
access |
En linea |
databasecode |
rev-scielo-mx |
tag |
revista |
region |
America del Norte |
libraryname |
SciELO |
language |
English |
format |
Digital |
author |
Rodríguez-Diez,Gerardo Márquez,Manlio F. Iturralde-Torres,Pedro Molina-Fernández de L.,Luis G. Pozas-Garza,Gerardo Cordero-Cabra,Alejandro Rojel-Martínez,Ulises |
spellingShingle |
Rodríguez-Diez,Gerardo Márquez,Manlio F. Iturralde-Torres,Pedro Molina-Fernández de L.,Luis G. Pozas-Garza,Gerardo Cordero-Cabra,Alejandro Rojel-Martínez,Ulises Joint Mexican position document on the treatment of atrial fibrillation |
author_facet |
Rodríguez-Diez,Gerardo Márquez,Manlio F. Iturralde-Torres,Pedro Molina-Fernández de L.,Luis G. Pozas-Garza,Gerardo Cordero-Cabra,Alejandro Rojel-Martínez,Ulises |
author_sort |
Rodríguez-Diez,Gerardo |
title |
Joint Mexican position document on the treatment of atrial fibrillation |
title_short |
Joint Mexican position document on the treatment of atrial fibrillation |
title_full |
Joint Mexican position document on the treatment of atrial fibrillation |
title_fullStr |
Joint Mexican position document on the treatment of atrial fibrillation |
title_full_unstemmed |
Joint Mexican position document on the treatment of atrial fibrillation |
title_sort |
joint mexican position document on the treatment of atrial fibrillation |
description |
Abstract Atrial fibrillation (AF) is a frequent arrhythmia; its prevalence is near 2% in the general population; in Mexico, more than one-half million people are affected. AF needs to be considered as a public health problem. Because AF is an independent risk factor associated with mortality, due to embolic events, heart failure, or sudden death; early diagnosis is of utmost importance. In unstable patients with a recent onset of AF, electrical cardioversion should be practiced. In stable patients, once thromboembolic measures have been taken, it is necessary to assess whether it is reasonable to administer an antiarrhythmic drug to restore sinus rhythm or performed electrical cardioversion. For recidivating cases of paroxysmal and persistent presentation, the most effective strategy is performed pulmonary vein isolation with either radiofrequency or cryoballoon energy. Permanent AF is that in which recovery of sinus rhythm is not possible, the distinguishing feature of this phase is the uncontrollable variability of the ventricular frequency and could be treated pharmacologically with atrioventricular (AV) nodal blockers or with a VVIR pacemaker plus AV nodal ablation. The presence of AF has long been associated with the development of cerebral and systemic (pulmonary, limb, coronary, renal, and visceral) embolism. The prevention of embolisms in valvular AF should perform with Vitamin K antagonists (VKA). For patients with AF not associated with mitral stenosis or a mechanical valve prosthesis, a choice can be made between anticoagulant drugs, VKA, or direct oral anticoagulants. Antiplatelet agents have the weakest effect in preventing embolism. |
publisher |
Instituto Nacional de Cardiología Ignacio Chávez |
publishDate |
2020 |
url |
http://www.scielo.org.mx/scielo.php?script=sci_arttext&pid=S1405-99402020000100069 |
work_keys_str_mv |
AT rodriguezdiezgerardo jointmexicanpositiondocumentonthetreatmentofatrialfibrillation AT marquezmanliof jointmexicanpositiondocumentonthetreatmentofatrialfibrillation AT iturraldetorrespedro jointmexicanpositiondocumentonthetreatmentofatrialfibrillation AT molinafernandezdelluisg jointmexicanpositiondocumentonthetreatmentofatrialfibrillation AT pozasgarzagerardo jointmexicanpositiondocumentonthetreatmentofatrialfibrillation AT corderocabraalejandro jointmexicanpositiondocumentonthetreatmentofatrialfibrillation AT rojelmartinezulises jointmexicanpositiondocumentonthetreatmentofatrialfibrillation |
_version_ |
1756226638607024128 |